Niacin News and Research

RSS

Niacin (also known as vitamin B3, nicotinic acid and vitamin PP) is an organic compound with the formula C5H4NCO2H and, depending on the definition used, one of the between forty to eighty essential human nutrients.

ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol

The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet, could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol. Caution, the ESC experts advise, should be displayed in the interpretation of the results.

26 Jul 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.

21 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Vertellus announces new 3-cyanopyridine production unit at Nantong facility

Vertellus Specialties Inc. announced today that it will break ground on a new 3-cyanopyridine production unit at Vertellus' production facility in Nantong, Jiangsu, China. This unit is a continuation of a larger effort to expand production capacity in Nantong. It will increase Vertellus' Vitamin B3 manufacturing capacity in the region by 10,000 metric tons. The capacity increase will enable Vertellus to maintain its position as the world's second largest provider of Vitamin B3 and the largest producer of cyanopyridines in the world.

8 Jun 2010

Foods advertised on TV oversupply nutrients associated with chronic illness: Study

Making food choices based on television advertising results in a very imbalanced diet according to a new study comparing the nutritional content of food choices influenced by television to nutritional guidelines published in the June issue of the Journal of the American Dietetic Association.

1 Jun 2010

Niacin fortification foods can cause obesity

Dietary factors have long been known to play a major role in the development of obesity. The global increasing prevalence of obesity suggests that there should be some common changes in diet worldwide.

21 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

FDA rejects experimental painkiller Acurox

In a new development King Pharmaceuticals Inc. and Acura Pharmaceuticals Inc. have failed to win the approval of a US panel for marketing an experimental painkiller called Acurox.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

High dose of Zocor could lead to muscle injury, warns FDA

The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg.

20 Mar 2010

Acurox NDA: FDA schedules Advisory Committee meeting

Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.

18 Mar 2010

Tips for reducing LDL cholesterol

Cardiovascular disease is the No.1 killer in North America. And high cholesterol is one of the primary risk factors of coronary heart disease and stroke. According to the Heart and Stroke Foundation, almost 40% of Canadian adults are classified as having high blood cholesterol levels.

16 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.

10 Mar 2010

Steroids and weight loss products can accelerate hair loss, says hair loss expert

In a study due to be released next month, the world's leading hair transplant and hair loss expert Dr. Larry Shapiro will show that men and women have been losing their hair from using popular weight loss and work out products that contain whey protein isolate- and it's not just their genes that are to blame.

19 Feb 2010

Barley beta-glucan soluble fiber lowers cholesterol and reduces risk for coronary heart disease

According to statistics from the Centers for Disease Control and Prevention, heart disease continues to be the leading cause of death in the United States and is also a major cause of disability. But the good news is improving heart health can be as easy as making simple lifestyle changes like choosing foods with proven heart health-promoting attributes.

11 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010